Colorectal cancer researchers from Vanderbilt-Ingram Cancer Center (VICC) have been awarded a Specialized Program of Research Excellence grant from the National Cancer Institute (NCI).
News: Gastrointestinal Cancer Research Program
Inflammation synergizes with a cell’s intrinsic genetic program to promote the development of pancreatic cancer.
Investigators are exploring the molecular mechanisms behind the association of chronic inflammation and colon cancer.
Cellular soldiers created using the body’s own defenses can track down and kill escaping cancer cells during surgeries, preventing metastasis and saving lives, a Vanderbilt University biomedical engineer has discovered, particularly in cases of triple negative breast cancer.
Researchers have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori to inject a cancer-causing protein into the stomach lining.
Fish oil supplementation provides a modest but beneficial effect on reducing molecules associated with colorectal cancer development.
Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
A recent study demonstrates that loss of the receptor NOD1 augments inflammatory and injury responses to H. pylori – and points towards NOD1 as a prime target for modification for either preventing or treating H. pylori infections.
A report by researchers at Vanderbilt University Medical Center has shattered conventional wisdom about how cells, including cancer cells, shed DNA into the bloodstream: they don’t do it by packaging the genetic material in tiny vesicles called exosomes.
Vanderbilt investigators report that a medicine currently being tested as a chemoprevention agent for multiple types of cancer can also act directly reduce the virulence of Helicobacter pylori, the primary cause of gastric cancer.